|
|
Vaccine Detail
|
L612 HuMAb |
| Vaccine Information |
- Vaccine Name: L612 HuMAb
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007631
- Type: human IgM monoclonal antibody
- Status: Licensed
- Antigen: GM3
- Immunization Route: Intramuscular injection (i.m.)
- Description: The human IgM monoclonal antibody, L612 HuMAb, was well tolerated. Infusion of L612 HuMAb appears to produce significant antitumor activity in melanoma patients (Irie et al., 2004).
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Serum antibody levels peaked 24 to 48 h after starting the infusion (Irie et al., 2004).
|
| References |
Irie et al., 2004: Irie RF, Ollila DW, O'Day S, Morton DL. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer immunology, immunotherapy : CII. 2004; 53(2); 110-117. [PubMed: 14564483].
|
|
